Patients in the KEYNOTE trials received
pembrolizumab intravenously at doses of 2 mg / kg or 10 mg / kg every three weeks, or 10 mg / kg every two weeks.
Not exact matches
The KEYNOTE - 45 study randomised 542 patients from 29 countries between November 2014 and November 2015 to either
pembrolizumab (200 mg, given
intravenously once every three weeks for up to 24 months) or one of three chemotherapy options chosen by study investigators.
Pembrolizumab 200 mg was then administered
intravenously every 2 weeks.